

EORTC GITCG MEETING 2019

31 October – 2 November 2019

Tallinn, Estonia - House of the Blackheads

Thursday 31 October 2019		
Task Forces		
Time slot	Topic	Speaker
14.00-14.05	Welcome and introduction	F. Lordick E. Smyth
Task Force Sessions		
14.05 – 14.40	Esophagus + Stomach Cancer	M. Moehler / D. Wagner
14.40 – 15.20	Hepatobiliary, Pancreas and NET Cancer	J. W. Valle / J. Ricke
15.20 – 16.00	Colorectal Cancer	M. Peeters / T. Kössler/ F. Sclafani
16.00 – 16.20	Coffee Break	
Task Force Sessions		
16.20 – 17.00	Rectum & Anal Cancer	D. Arnold / L. Wyrwicz
17.00 – 17.40	Adolescents and Young Adults (AYA)	I. Ben Aharon / E. Fontana
17.40 – 18.20	SPECTA and Early Phase trials	R. Obermannova / M. Alsina
18.20 – 18.40	Novel imaging biomarkers for response assessment and survival estimation	W. Kunz

EORTC GITCG MEETING 2019

31 October – 2 November 2019

Tallinn, Estonia - House of the Blackheads

Friday 1 November 2019		
GITCG Studies		
Time slot	Topic	Speaker
8.00 – 09.15	Business Meeting <i>(restricted to Group members taking part in the strategy meetings)</i>	F. Lordick
09.15 – 09.45	Election of new chairman of the GITCG <i>All active members</i>	Applicant(s)
09.45 – 10.15	Report from AACR-NCI-EORTC meeting 2019	E. Fontana / I. Ben-Aharon
10.15 – 11.30	Coffee Break	
11.30 – 12.15	Young Investigators Program <ul style="list-style-type: none"> ▪ update project J. Barriuso ▪ update project S. Markar ▪ OncoTev-2 results – 2015 YI project C. Cella 	A.Roth / R. Salazar J. Barriuso S. Markar M. Knoedler
12.15 – 13.00 <i>10 min per study</i>	Protocols in PRE-development (1) <ul style="list-style-type: none"> ▪ 1912-GITCG PAMICC ▪ 1925-GITCG PANORAMA ▪ 1927-GITCG CIRCULATE ▪ 1933-ROG-GITCG PANCREAS SBRT 	Moderator E. Smyth
13.00 – 14.00	Lunch	

EORTC GITCG MEETING 2019

31 October – 2 November 2019

Tallinn, Estonia - House of the Blackheads

Friday 1 November 2019		
GITCG Studies		
Time slot	Topic	Speaker
14.00 – 15.30 <i>10 min per study</i>	<p>Protocols in PRE-development (2)</p> <ul style="list-style-type: none"> ▪ 1937-GITCG ASA NELM ▪ 1938-GITCG TOledo ▪ Incidental gallbladder Intergroup ▪ SPECTA - RP 1904 LMGC <p>Protocols in regulatory submission</p> <ul style="list-style-type: none"> ▪ 1607-GITC ABC-09 BTC PEMBRO ▪ 1715-GITCG TELEFIRST <p>Recruiting studies (1)</p> <ul style="list-style-type: none"> ▪ 1741-GITCG DYNAMIC ▪ 1714-ROG-GITCG CRUCIAL ▪ 1707-GITCG VESTIGE 	
15.30 – 15.45	Coffee Break	
15.45 – 17.00 <i>10 min per study</i>	<p>Recruiting studies (2)</p> <ul style="list-style-type: none"> ▪ 1560-GITCG ILOC ▪ 1527 DREAM ▪ 1203 INNOVATION ▪ RP-1828 CRC IMMUcan ▪ 1534 SAKK 41/13 - ASPIRIN ▪ 22114-40111 TOP GEAR <p>Studies closed for recruitment</p> <ul style="list-style-type: none"> ▪ 1409-GITCG CLIMB ▪ 40CRC SPECTAcolor (+ medical review) 	
17.00 – 17.15	Closing remarks	F. Lordick
20.00	Dinner	

EORTC GITCG MEETING 2019

31 October – 2 November 2019

Tallinn, Estonia - House of the Blackheads

Saturday 2 November 2019		
Scientific Symposium		
Time slot	Topic	Speaker
Session 1	Chair of the session: Prof Eric Van Cutsem	
9.00 – 9.25	Interaction between neoadjuvant therapies, comorbidity and surgery, in relation to surgical short-term and oncological long-term outcomes	Prof. Magnus Nilsson
9.25 – 9.50	Systemic therapy of advanced gastric cancer - do markers and patient characteristics guide treatment	Prof. Florian Lordick
9.50-10.15	How molecular biology informs contemporary treatment of Crc	Dr. Elisa Fontana
10.15-10.30	Discussion	
10.30 – 11.00	Coffee Break	
Session 2	Chairs of the session: Markus Möhler and Elizabeth Smyth	
11.00-11.25	Early Onset Colorectal Cancer - Changing Face of a Common disease.	Prof. Irit Ben-Aharon
11.25-11.50	Repeated centralised resectability assessment in 1086 Finnish metastatic colorectal cancer patients (the RAXO study)	Dr. Pia Österlund
11.50-12.15	Anal Cancer - how to expand treatment options in the International Rare Cancer Initiative	Dr. Rachel Riechelman
12.15-12.45	Discussion and closing remarks: Perspective for the Future of GI Cancer research	Prof. Dirk Arnold
12.45 – 13.00	Closing remarks	Prof. F. Lordick